Interestingly, they also found no difference in arterial stiffness between IBD subgroups based on the type of therapy, which included monoclonal antibody biologics (which mimic the immune system response and include drugs that target TNF-alpha, e.g., infliximab), aminosalicylates (e.g., sulfasalazine, olsalazine), and disease-modifying antirheumatic drugs (DMARD, e.g. methotrexate, hydroxychloroquine) [28-30]. The gene discussed is TNF; the disease is inflammatory bowel disease.